Starbucks Stops Paying for Weight Loss Drugs Starting in October

Starbucks is making a big change to its health plan. Starting in October, the company will stop covering GLP-1 drugs for weight loss. This affects any employee who works at least 20 hours a week and qualifies for benefits.

But there’s a catch worth knowing. If a doctor prescribes the same drug for something else, like diabetes, it will still be covered. So the coverage isn’t disappearing completely. It’s just getting narrower.

A Starbucks spokesperson confirmed the news. However, they didn’t share any extra details about the decision.

Why is this happening? Simply put, the cost got too high.

Drugs like Ozempic and Wegovy started as diabetes treatments. Later, doctors began prescribing them for weight loss too. And people loved the results. These drugs work by copying hormones in your body that control hunger and blood sugar. That’s why they help with obesity. But that’s also why they need a prescription and regular checkups with a doctor.

Here’s the bigger picture. Obesity isn’t just about weight. It raises the risk of heart disease, type 2 diabetes, and other serious health issues. That’s exactly why so many companies added these drugs to their health plans in the first place. They wanted to help employees stay healthy.

But then the bills started piling up.

A 2026 survey looked into this. It found that GLP-1 drugs accounted for 11.4% of total health claims among employers last year. In 2023, that number was only 6.9%. That’s a huge jump in just a few years.

The same survey found something else too. About 36% of employers covered these drugs for both diabetes and weight loss in 2026. Meanwhile, 60% only covered them for diabetes. Starbucks is now joining that second group.

This isn’t just about GLP-1 drugs, though. Health costs overall are climbing fast. Costs per employee went up 6% last year. And experts predict a 6.7% rise this year. GLP-1 spending is a major reason for that increase.

Starbucks isn’t alone in this decision. Allina Health already stopped covering these drugs for weight loss. PwC reportedly did the same thing. So this looks like a growing trend, not a one-time move.

Now, what does this mean for employees? If you lose coverage, the price can be steep. Some people pay over $1,000 a month without insurance. And stopping these drugs isn’t easy either. Many people gain the weight back once they stop taking them, since GLP-1 medications require ongoing use to keep results.

So what should affected employees do? Talk to your doctor as soon as possible. Ask about other treatment options. There may be savings programs or different medications that could help.

More companies may follow Starbucks’ lead. Health costs keep rising, and businesses are looking for ways to manage them. This story is likely just the beginning.